(…) Predicted manufacturing costs (US dollars) for 12-week courses of HCV DAAs were $21–$63 for ribavirin, $10–$30 for daclatasvir, $68–$136 for sofosbuvir, $100–$210 for faldaprevir, and $130–$270 for simeprevir
(…) access (…) at minimum prices (…) will strongly depend on the level of enforcement of patent restrictions.
These price estimates are based on the previous experience with production of ARVs for HIV treatment, which assumes market competition through generic manufacture.
Legal mechanisms such as voluntary or compulsory licenses may be needed to overcome patent barriers and stimulate such competition. (…)
(…) “evergreen” patenting (…) could further delay the introduction of generic DAAs (…)
–> See ´Discussion´ for quintessence!
Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
Andrew Hill (1), Saye Khoo(1), Joe Fortunak (2), Bryony Simmons (3) and Nathan Ford (4)
1Department of Pharmacology and Therapeutics, Liverpool University, United Kingdom; 2Chemistry and Pharmaceutical Sciences, Howard University, Washington, District of Columbia; 3Imperial College London, United Kingdom; and 4Centre for Disease Epidemiology and Research, University of Cape Town, South Africa
Clin Infect Dis. (2014) 58 (7): 928-936